Please Wait
Applying Filters...
menu
    • menu
    J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

    Data Compilation
    #PharmaFlow

    Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

    Stock Recap
    #PipelineProspector

    Menu

    Labetalol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 152Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    28/06/2025 Procos
    Italy
    		 Procos S. p. A. 224MF10101 Labetalol Hydrochloride GR 2012-05-25 2012-05-25 Via Matteotti 249,28062 CAMERI (NOVARA)/ITALY
    28/06/2025 Procos
    Italy
    		 Procos S. p. A. 218MF10992 Labetalol Hydrochloride 2006-12-18 2006-12-18 Via Matteotti 249,28062 CAMERI(NOVARA)/ITALY